Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Post by MrMugsyon Jan 25, 2023 10:34am
461 Views
Post# 35245031

For those of you following ...

For those of you following ...Stauffer has been on the Biofuse board.
He is now the Chairman.

The only reason I bring it up ... been wondering how closely this kind of technology and our future wound healing medication might find synergy in the market.

H2S products in gel form ... during the operation ... promoting quicker healing.  More of an acute opportuntiy vs. chronic opportunity.  That's good from  the liver perspective.

Just put it in the parking lot as something we can discuss in the future.

---------------

BioFuse Medical Technologies, Inc. is pleased to announce the appointment of Dr. Joe Stauffer as Chairman of the Board of Directors. Dr. Stauffer is an executive biotech physician and CEO/Founder of Alta Life Sciences, LLC., a pharmaceutical and investment advisory firm based in Sarasota, FL. He is also currently the Chief Medical Officer (CMO) of Antibe Therapeutics, a Toronto based public biotech.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities